Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hantaan and Puumala Virus DNA Vaccines via PharmaJet Stratus
NCT02776761Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2016
- Primary completion
- Sep 2017
- Modality
- DNA Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of hantavax and Puumala virus DNA vaccine in Hantaan virus infection and nephropathia epidemica (NE) (3 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Number of Adverse Events at 365 days. Started Aug 2016; status: completed.
02
Drugs
hantavaxPuumala virus DNA vaccine
03
Conditions
Hantaan virus infectionnephropathia epidemica (NE)
Beyond the preview
Go deeper on NCT02776761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776761.